• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    InflaRx Data Bolsters Izicopan as Top C5aR Inhibitor

    GLOBENEWSWIRE

    InflaRx Showcases Vilobelimab`s Efficacy In Pyoderma Gangrenosum

    GLOBENEWSWIRE

    Inflarx Present Vilobelimab Ph3 Results For Pyoderma Gangrenosum

    GLOBENEWSWIRE

    InflaRx To Report Full Year 2025 Results On March 19, 2026

    GLOBENEWSWIRE

    Inflarx Announces Participation In February Investor Conferences

    GLOBENEWSWIRE

    Inflarx Updates Ph3 Data For Vilobelimab In Pyoderma Gangrenosum

    GLOBENEWSWIRE

    InflaRx Reports Positive Phase 2a Data for INF904 in HS & CSU

    GLOBENEWSWIRE

    InflaRx To Report Topline Ph2a Data For INF904 In HS And CSU

    GLOBENEWSWIRE

    Inflarx To Participate In Guggenheim Healthcare Innovation Conf

    GLOBENEWSWIRE

    InflaRx Reports Q2 2025 Financials, Updates on Business

    GLOBENEWSWIRE

    InflaRx To Showcase Vilobelimab In Immuno-Dermatology At AAD

    GLOBENEWSWIRE

    InflaRx To Participate In Guggenheim SMID Cap Biotech Conference

    GLOBENEWSWIRE

    InflaRx Gains EU Approval For Novel ARDS Treatment GOHIBIC

    GLOBENEWSWIRE

    InflaRx Receives CHMP Opinion for GOHIBIC® in SARS-CoV-2 ARDS

    GLOBENEWSWIRE

    InflaRx Shows Vilobelimab Potential Synergy In Severe COVID-19 At ATS

    GLOBENEWSWIRE

    InflaRx Participates at Capital One Biotech Event

    GLOBENEWSWIRE

    InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab

    GLOBENEWSWIRE

    InflaRxs Marketing Authorization Application (MAA) for Vilobelimab

    GLOBENEWSWIRE

    InflaRx Announces Commercial Launch of Gohibic vilobelimab

    GLOBENEWSWIRE

    InflaRx plans to launch Covid antibody with five-figure price tag

    ENDPTS

    InflaRx Receives FDA Emergency Use Authorization for Gohibic

    GLOBENEWSWIRE

    FDA authorizes InflaRx`s anti-inflammation drug for severe COVID

    FIERCE PHARMA

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.